INOVATYON/ ENGOT-ov5 study: Randomized phase III international study comparing trabectedin/pegylated liposomal doxorubicin (PLD) followed by platinum at progression vs carboplatin/PLD in patients with recurrent ovarian cancer progressing within 6-12 months after last platinum line.
N Colombo, A Gadducci, J Sehouli, E Rulli, J Mäenpää, C Sessa, A Montes, N B Ottevanger, R Berger, I Vergote, M D'Incalci, C Churruca Galaz, R Chekerov, G B Nyvang, S Riniker, R Herbertson, R Fossati, M P Barretina-Ginesta, M Deryal, M R Mirza, E Biagioli, M Iglesias, G Funari, M Romeo, G Tasca, B Pardo, G Tognon, M J Rubio-Pérez, A DeCensi, U De Giorgi, P Zola, P Benedetti Panici, M Aglietta, V Arcangeli, C Zamagni, A Bologna, A Westermann, V Heinzelmann-Schwarz, I Tsibulak, P Wimberger, A Poveda
British journal of cancer 2023;128(8):1503-1513